中國杭州，2023 年6月3日——百力司康生物醫(yī)藥（杭州）有限公司（“百力司康”），一家致力于研究和開發(fā)差異化抗體偶聯(lián)藥物（ADC）的臨床階段的生物醫(yī)藥公司，宣布將在2023 年6月2日至6日舉行的美國臨床腫瘤學(xué)會（2023 ASCO 年會）上公布BB-1701 的Ⅰ期研究數(shù)據(jù)。 在這次會議上，將以海報的形式展示BB-1701在局部晚期/轉(zhuǎn)移性HER2表達實體瘤受試者中的劑量遞增的首次人體Ⅰ期研究，包括安全性、耐受性、藥代動力學(xué)和抗腫瘤活性數(shù)據(jù)。 2023年5月8日，百力司康與衛(wèi)材株式會社（總部：東京，“衛(wèi)材”）宣布就 BB-1701 達成臨床試驗合作，百力司康將與衛(wèi)材合作推進BB-1701的開發(fā)，造福全世界的患者。 摘要標題：評估BB-1701在局部晚期/轉(zhuǎn)移性HER2表達實體瘤受試者中的安全性、耐受性、藥代動力學(xué)和抗腫瘤活性的開放、多劑量、劑量遞增、隊列擴展的首次人體Ⅰ期研究 摘要編號：3029 分會場標題：發(fā)展療法 - 分子靶向藥物和腫瘤生物學(xué) 展示時間：2023年6月3日（周六）8:00 AM-11:00 AM/北京時間2023年6月3日（周六）9:00 PM-12:00 PM 關(guān)于BB-1701 BB-1701是一款由百力司康開發(fā)的由抗HER2抗體和艾立布林結(jié)合的ADC創(chuàng)新藥，旨在為局部晚期和轉(zhuǎn)移性HER2陽性實體瘤患者提供更加安全有效的治療方案, 具有應(yīng)用于多種腫瘤適應(yīng)癥的市場前景。BB-1701具有獨特的作用機制（MOA），包括有效的旁路殺傷效應(yīng)以及免疫原性細胞死亡（ICD）活性，目前正在進行中美I/II期國際多中心臨床試驗。 1 關(guān)于百力司康生物醫(yī)藥（杭州）有限公司
百力司康生物醫(yī)藥（杭州）有限公司（“百力司康”）由醫(yī)藥界富有經(jīng)驗的海歸博士于2017年在浙江省杭州市錢塘區(qū)共同創(chuàng)建，是一家專注于抗腫瘤生物創(chuàng)新藥的研發(fā)和產(chǎn)業(yè)化的臨床階段的生物醫(yī)藥企業(yè)。百力司康擁有獨特的自主知識產(chǎn)權(quán)技術(shù)平臺、豐富的ADC產(chǎn)品管線，以及能夠支持抗體和ADC生產(chǎn)并應(yīng)用于臨床開發(fā)和早期商業(yè)化的GMP自有產(chǎn)能。百力司康已被認定為中國國家高新技術(shù)企業(yè)。秉承著“集百家之力，司大眾之康”的公司核心價值理念，通過與國內(nèi)外同行密切合作，百力司康會繼續(xù)聚焦創(chuàng)新藥，解決未滿足的臨床需求。 有關(guān)百力司康的更多信息，請訪問 https://www.blissbiopharma.com。 2 關(guān)于衛(wèi)材 衛(wèi)材的企業(yè)理念是“將患者利益和公眾健康放在首位，為提升其福祉做出貢獻?！被谶@一理念（也稱為我們的關(guān)心人類健康（hhc）理念），公司的目標是通過緩解對健康的焦慮和減少健康差距，有效地為實現(xiàn)健康社會做出貢獻。憑借由研發(fā)場地、生產(chǎn)基地和營銷子公司組成的全球網(wǎng)絡(luò)，針對醫(yī)療需求高度未滿足的疾病，公司努力創(chuàng)造和交付創(chuàng)新產(chǎn)品，特別關(guān)注神經(jīng)病學(xué)和腫瘤學(xué)戰(zhàn)略領(lǐng)域。 此外，我們與全球合作伙伴共同開展的各項活動表明，我們繼續(xù)致力于消除被忽視的熱帶疾病，這是聯(lián)合國可持續(xù)發(fā)展目標（SDG）的目標之一（3.3）。 有關(guān)衛(wèi)材的更多信息，請訪問www.Eisai.com（全球總部：衛(wèi)材株式會社），并通過Twitter、LinkedIn和Facebook聯(lián)系。 3 媒體問詢 百力司康生物醫(yī)藥（杭州）有限公司 電話：+86-0571-86808367 郵箱：office@blissbiopharma.com BLISSBIO TO PRESENT DATA ON BB-1701 PHASE 1 STUDY AT 2023 ASCO ANNUAL MEETING Hangzhou, China, June 3, 2023 -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, (“BlissBio”) a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced today BB-1701 Phase 1 study data will be presented at the American Society of Clinical Oncology (2023 ASCO Annual Meeting), to be held from June 2 to 6, 2023. At this meeting, there will be a poster presentation on safety, tolerability, pharmacokinetics, and antitumor activity in a first-in-human dose escalation Phase I study of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. As announced on May 8, 2023, BlissBio and Eisai Co., Ltd (Headquarters: Tokyo, “Eisai”) entered into a clinical trial collaboration for BB-1701, and BlissBio works with Eisai to advance the development of BB-1701 for the benefit of patients worldwide. Abstract Title: A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. Abstract Number: 3029 Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology Session Date and Time: 8:00am-11:00am (CDT), June 3rd, 2023 About BB-1701 BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2-expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is conducting Phase I/II international clinical trials both in China and US. 1 About Bliss Biopharmaceutical (Hangzhou) Co., Ltd Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated on discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs. For more information please visit https://www.blissbiopharma.com 2 About Eisai Co., Ltd Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as our human health care (hhc) Concept), the company aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, the company’s continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter, LinkedIn and Facebook. 3 Media Inquiries Bliss Biopharmaceutical (Hangzhou) Co., Ltd TEL: +86-0571-86808367 E-mail: office@blissbiopharma.com
聲明：本文觀點僅代表作者本人，不代表煜森資本立場，歡迎在留言區(qū)交流補充。如需轉(zhuǎn)載，請注明文章作者和來源。如涉及作品內(nèi)容、版權(quán)和其它問題，請在本平臺留言。
